On September 15, Guardant Health Inc. rose 5.31% in regular trading, trading at $176.525/share, with turnover of $189 million. The rally was driven by the announcement that Evernorth's Evicore has agreed to include the company's Shield blood test in its colorectal cancer screening coverage, effective January 1, 2027.

This latest agreement builds on a similar deal reached with Carelon, which took effect on November 15 and expanded commercial insurance coverage for Shield to approximately 90 million people, representing roughly 75% of eligible U.S. patients. The addition of Evicore coverage further broadens Shield's commercial reach. Shield is an FDA-approved blood test for primary colorectal cancer screening in average-risk adults aged 45 and older.

The coverage expansion comes amid a series of positive catalysts for the company, including recent FDA approvals of Guardant360 CDx as a companion diagnostic for both advanced breast cancer and HER2-mutant non-small cell lung cancer, as well as UBS raising its price target to $225 from $175 while maintaining a Buy rating. Analysts polled by FactSet assign the stock an average Buy rating with a mean price target of $198.38.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)